Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (141-150 of 323) with videos related to

Pageof 33
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
Tumori|January 7, 2023
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patientsBeatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, et al.
ESMO Open|December 7, 2017
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical studyChiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, et al.
Scientific Reports|April 26, 2020
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
ESMO Open|June 25, 2019
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectableElena Ongaro, Chiara Cremolini, Daniele Rossini, et al.
Journal of the National Cancer Institute|May 24, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancerAlessandra Raimondi, Gabriele Tinè, Valerie Boige, et al.
Therapeutic Advances in Medical Oncology|February 26, 2026
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancerAndrea Pretta, Riccardo Giampieri, Pina Ziranu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitorsFrancesca Corti, Sara Lonardi, Rossana Intini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Journal of Translational Medicine|May 8, 2016
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational studyFilippo Pietrantonio, Rosa Berenato, Claudia Maggi, et al.
Pageof 33

Showing results (141-150 of 323) with videos related to

Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
Tumori|January 7, 2023
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patientsBeatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, et al.
ESMO Open|December 7, 2017
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical studyChiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, et al.
Scientific Reports|April 26, 2020
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
ESMO Open|June 25, 2019
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectableElena Ongaro, Chiara Cremolini, Daniele Rossini, et al.
Journal of the National Cancer Institute|May 24, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancerAlessandra Raimondi, Gabriele Tinè, Valerie Boige, et al.
Therapeutic Advances in Medical Oncology|February 26, 2026
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancerAndrea Pretta, Riccardo Giampieri, Pina Ziranu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitorsFrancesca Corti, Sara Lonardi, Rossana Intini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Journal of Translational Medicine|May 8, 2016
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational studyFilippo Pietrantonio, Rosa Berenato, Claudia Maggi, et al.
Pageof 33